ZAI LAB LIMITED (ZLAB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 428.58M USD | Liabilities, Current |
| Cash and equivalents | 607.52M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 69.59M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 90.89M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $428.58M | $607.52M | (m) | $69.59M | $90.89M | (m) |
| 2026-03-31 | (m) | $392.98M | $651.32M | (m) | $54.07M | $85.96M | (m) |
| 2025-12-31 | (m) | $416.17M | $679.57M | (m) | $106.12M | $74.75M | (m) |
| 2025-09-30 | (m) | $359.77M | $717.15M | (m) | $85.38M | $67.14M | (m) |
| 2025-06-30 | (m) | $331.50M | $732.16M | (m) | $88.50M | $61.70M | (m) |
| 2025-03-31 | (m) | $319.81M | $757.26M | (m) | $76.56M | $53.05M | (m) |
| 2024-12-31 | (m) | $299.38M | $449.67M | (m) | $85.18M | $39.88M | (m) |
| 2024-09-30 | (m) | $286.31M | $616.09M | (m) | $49.97M | $39.55M | (m) |
| 2024-06-30 | (m) | $251.72M | $630.05M | (m) | $69.64M | $41.85M | (m) |
| 2024-03-31 | (m) | $192.11M | $650.78M | (m) | $60.42M | $37.85M | (m) |
| 2023-12-31 | (m) | $203.07M | $790.15M | (m) | $59.20M | $44.83M | (m) |
| 2023-09-30 | (m) | $124.90M | $788.81M | (m) | $41.60M | $44.23M | (m) |
| 2023-06-30 | (m) | $133.35M | $859.15M | (m) | $47.28M | $36.35M | (m) |
| 2023-03-31 | (m) | $124.56M | $879.84M | (m) | $43.35M | $38.41M | (m) |
| 2022-12-31 | (m) | $139.84M | $1.01B | (m) | $39.96M | $31.62M | (m) |
| 2022-09-30 | (m) | $155.55M | $1.12B | (m) | $27.74M | $29.13M | (m) |
| 2022-06-30 | (m) | $168.88M | $680.82M | (m) | $27.05M | $23.34M | (m) |
| 2022-03-31 | (m) | $154.91M | $846.96M | (m) | $33.39M | $20.29M | (m) |
| 2021-12-31 | (m) | $192.90M | $964.10M | (m) | $47.47M | $18.95M | (m) |
| 2021-09-30 | (m) | $112.01M | $1.40B | (m) | $21.02M | $12.49M | (m) |
| 2021-06-30 | (m) | $193.92M | $1.77B | (m) | $18.03M | $11.11M | (m) |
| 2021-03-31 | (m) | $92.66M | $1.01B | (m) | $8.81M | $12.63M | (m) |
| 2020-12-31 | (m) | $98.04M | $442.12M | (m) | $5.17M | $13.14M | (m) |
| 2020-09-30 | (m) | (m) | $175.88M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $56.55M | $258.60M | (m) | $7.02M | $6.57M | (m) |
| 2020-03-31 | (m) | (m) | $363.58M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $46.63M | $75.93M | (m) | $3.79M | $6.00M | (m) |
| 2019-09-30 | (m) | $41.05M | $68.71M | (m) | $3.92M | $889.43K | (m) |
| 2019-06-30 | (m) | (m) | $91.60M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $48.84M | $62.95M | (m) | $89.71K | $3.82K | (m) |
| 2018-09-30 | (m) | (m) | $104.96M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $12.07M | $229.66M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.17M | $83.95M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $13.16M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $7.15M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |